• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

New Yale Report to Show Devastating Impact of Diabetes Epidemic By 2025: Novo Nordisk to Launch National Changing Diabetes Program to Stem Tide of Diabetes Epidemic and Reduce Barriers to Prevention and Care

Posted on: Thursday, 3 November 2005, 12:00 CST

Results of a joint report by the Yale School of Public Health and Medicine and the Institute for Alternative Futures will be announced November 9. The report forecasts the dramatic consequences of the diabetes epidemic including projections in 2025 on the staggering number of deaths associated with diabetes as well as the cases of blindness and amputations if the barriers to diabetes prevention and treatment are not seriously addressed and care is not improved in the United States.

Novo Nordisk, the sponsor of the report, will also launch its groundbreaking National Changing Diabetes Program. Please join us for a special breakfast briefing to learn about this significant report, as well as the unprecedented social and financial commitment that Novo Nordisk will announce to combat the barriers to diabetes prevention and treatment, thereby markedly improving diabetes care. The briefing will feature brief presentations by the following diabetes and healthcare experts before opening the floor to questions from the media:

-- Dr. Derek Yach, Professor and Head of Global Health at the

Yale School of Public Health and Medicine

-- Martin Soeters, President, Novo Nordisk USA

-- Newt Gingrich, Former Speaker of the House and Founder of the

Center for Health Transformation

-- Dr. Francine Kaufman, former President of the American

Diabetes Association, author of "Diabesity" and current Head

of the Center for Diabetes, Endocrinology and Metabolism at

Childrens Hospital Los Angeles and Professor of Pediatrics,

Keck School of Medicine of the University of Southern

California When: Wednesday November 9th, 2005 10:00 am Where: National Press Club 529 14th St. NW, 13th Floor in the Edward R. Murrow Room Please RSVP to Joe Wagner at 202-572-2979 or joe.wagner@gmmb.com if you plan to attend.

Novo Nordisk is a healthcare company with an 80-year history of innovation and achievement in diabetes care. With the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems, Novo Nordisk is a world leader in diabetes care. In addition to diabetes care, Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to economic success, environmental soundness, and social responsibility to employees and customers. For more information, visit www.novonordisk-us.com.

Source: Business Wire

More News in this Category